DIN 02489430 — ZIRABEV 100 MG
ZIRABEV is a solution of Bevacizumab marketed by PFIZER CANADA ULC. The full Bevacizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02489430
- Brand name
- ZIRABEV
- Active ingredient
- Bevacizumab
- Strength
- 100 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- PFIZER CANADA ULC
- Health Canada status
- MARKETED
- Drug class
- Vascular endothelial growth factor (VEGF) inhibitor (monoclonal antibody, antineoplastic agent)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Bevacizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02522179 | ABEVMY | 100 MG | SOLUTION | BIOCON BIOLOGICS CANADA INC | MARKETED |
| 02522160 | ABEVMY | 400 MG | SOLUTION | BIOCON BIOLOGICS CANADA INC | MARKETED |
| 02270994 | AVASTIN | 25 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02522829 | AYBINTIO | 100 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED |
| 02522837 | AYBINTIO | 400 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED |
| 02520729 | BAMBEVI | 100 MG | SOLUTION | APOTEX INC | MARKETED |
| 02520737 | BAMBEVI | 400 MG | SOLUTION | APOTEX INC | MARKETED |
| 02470748 | MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED |
| 02470756 | MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED |
| 02534177 | VEGZELMA | 100 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02534185 | VEGZELMA | 400 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02489449 | ZIRABEV | 400 MG | SOLUTION | PFIZER CANADA ULC | MARKETED |